Helsinn Healthcare
Helsinn Healthcare, a Swiss-based pharmaceutical company, has established itself as a leader in the oncology and supportive care sectors since its founding in 1977. Headquartered in Lugano, Switzerland, Helsinn operates globally, with significant presence in Europe, North America, and Asia. The company is renowned for its innovative approach to developing high-quality products that enhance the quality of life for cancer patients, including its flagship anti-emetic treatments. With a strong commitment to research and development, Helsinn has achieved notable milestones, including strategic partnerships and a robust pipeline of therapies. Its dedication to patient-centric solutions and a focus on unmet medical needs have positioned Helsinn as a trusted name in the healthcare industry, recognised for its contributions to cancer care and supportive therapies.
DitchCarbon Score
How does Helsinn Healthcare's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Helsinn Healthcare's score of 37 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Helsinn Healthcare's reported carbon emissions
In 2023, Helsinn Healthcare reported total carbon emissions of approximately 7,029,000 kg CO2e. This figure includes 2,245,000 kg CO2e from Scope 1 emissions, 45,000 kg CO2e from Scope 2 emissions, and 4,739,000 kg CO2e from Scope 3 emissions. Notably, the company achieved a significant reduction in Scope 2 emissions, decreasing them by about 89% from 2022 to 2023, reflecting a commitment to sustainability and energy efficiency. In 2022, Helsinn's total emissions were about 8,073,000 kg CO2e, with Scope 1 emissions at 1,770,000 kg CO2e, Scope 2 emissions at 404,000 kg CO2e, and Scope 3 emissions at 5,899,000 kg CO2e. The reduction in emissions from 2022 to 2023 indicates a proactive approach to mitigating climate impact. Helsinn's emissions data spans multiple years, showing a trend of increasing awareness and action towards reducing their carbon footprint. The company has set ambitious targets for emissions reduction, particularly in Scope 2, demonstrating their commitment to addressing climate change and enhancing their sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 2,955,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | - | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 00,000 |
| Scope 3 | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Helsinn Healthcare is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
